NCT04271332View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

December 22, 2024

Study Completion Date

March 23, 2025

Conditions
16P11.2 Deletion Syndrome
Interventions
DRUG

Arbaclofen

Arbaclofen tablet

DRUG

Placebo oral tablet

Manufactured to match Arbaclofen in size, shape, color and taste

Trial Locations (4)

10032

New York State Psychiatric Institute (NYSPI), New York

15031

Boston Children's Hospital, Boston

77054

Texas Children's Hospital, Houston

98915

University of Washington, Seattle

Sponsors
All Listed Sponsors
lead

Clinical Research Associates, LLC

OTHER